Zhai Weihua, Zhang Xiaoyu, Wei Jialin, Deng Qi, Dong Xiaoyuan, Zhang Xiaolei, Zhang Guixin, Ma Qiaoling, Zhang Rongli, Su Dong, Feng Sizhou, Han Mingzhe
Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin, China.
Department of hematology, the first center hospital of Tianjin.
Int J Infect Dis. 2015 Aug;37:97-103. doi: 10.1016/j.ijid.2015.04.015. Epub 2015 Apr 28.
Febrile neutropenia (FN) is a common but lethal complication of chemotherapy in hematological malignance. The aim of this study was to identify the prognostic risk factors for antibiotic treatment outcome in PN patients, and provide the optimal choice for the initial empirical antibiotic treatment.
227 consecutive FN hematologic malignancies from four hospitals in Northeast China were enrolled. The outcome of antibiotic therapy was investigated until 14 days after the onset of FN. The factors affecting antibiotic therapy outcome were evaluated using Univariate analysis and Multivariate logistic regression analysis.
Among all patients, 27 patients did not achieve favorable outcome either clinically or bacteriologically. It was shown that the risk factors for poor FN therapy outcome were associated with prolonged duration of neutropenia over 9 days during FN (P=0.019), slow neutrophil recovery (P=0.039), respiratory infection (P=0.005), and that initial monotherapy with drugs recommended by the guidelines indicated better outcome (P=0.009). Additionally, patients with multi-bacterial infection, as well as further ANC decrease after fever, had a poor prognosis.
Our results indicate that early application of antibiotics and prevention of respiratory infection as well as good clinical care are able to improve clinical outcomes from empirical antibiotic treatment in FN patients with hematological malignances.
发热性中性粒细胞减少(FN)是血液系统恶性肿瘤化疗常见但致命的并发症。本研究旨在确定FN患者抗生素治疗结果的预后风险因素,并为初始经验性抗生素治疗提供最佳选择。
纳入中国东北地区四家医院连续收治的227例FN血液系统恶性肿瘤患者。对FN发病后14天内的抗生素治疗结果进行调查。采用单因素分析和多因素logistic回归分析评估影响抗生素治疗结果的因素。
所有患者中,27例患者在临床或细菌学方面未取得良好结果。结果表明,FN治疗效果不佳的风险因素与FN期间中性粒细胞减少持续时间超过9天(P=0.019)、中性粒细胞恢复缓慢(P=0.039)、呼吸道感染(P=0.005)有关,并且指南推荐药物的初始单药治疗显示出更好的结果(P=0.009)。此外,多重细菌感染患者以及发热后ANC进一步下降者预后较差。
我们的结果表明,早期应用抗生素、预防呼吸道感染以及良好的临床护理能够改善血液系统恶性肿瘤FN患者经验性抗生素治疗的临床结果。